PubMed Health⌕ Search

PubMed · 14237449

FIBRINOGEN BREAKDOWN PRODUCTS.

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J H LEWIS, J H WILSON. 1964. FIBRINOGEN BREAKDOWN PRODUCTS.. https://doi.org/10.1152/ajplegacy.1964.207.5.1053

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Recombinant factor VIIa in massive postpartum haemorrhage.

Massive postpartum haemorrhage is a major cause of maternal and fetal morbidity and mortality. Management mainstays include transfusion therapy, uterotonic agents and surgery. The "off label" use of recombinant activated factor VII appears to have an evolving role in the management of massive postpartum haemorrhage refractory to conventional treatments. The current literature is reviewed.

Coagulants↗

[Use of activated recombinant FVII in the control of haemorrhage following trauma].

Uncontrolled haemorrhage is a major cause of death in trauma patients: sometimes inaccessible to surgery and often associated with coagulopathy. We report a case of severe blunt pelvic trauma associated with suicide. The conventional treatments were unsuccessful and embolization was impossible. The patient required massive blood product transfusion. A 100 microg/kg recombinant activated factor VII dose was infused, twice. After administration of the first dose, the blood requirement decreased dramatically. Further work and trials are required to assess the safety profile and dose regimen for this drug.

Coagulants↗